Etiology and pathogenesis of Parkinson's disease.

Parkinson's disease (PD) is an age-related neurodegenerative disorder that affects approximately 1 million persons in the United States. It is characterized by resting tremor, rigidity, bradykinesia or slowness, gait disturbance, and postural instability. Pathological features include degeneration of dopaminergic neurons in the substantia nigra pars compacta coupled with intracytoplasmic inclusions known as Lewy bodies. Neurodegeneration and Lewy bodies can also be found in the locus ceruleus, nucleus basalis, hypothalamus, cerebral cortex, cranial nerve motor nuclei, and central and peripheral components of the autonomic nervous system. Current treatment consists of a dopamine replacement strategy using primarily the dopamine precursor levodopa. While levodopa provides benefit to virtually all PD patients, after 5-10 years of treatment the majority of patients develop adverse events in the form of dyskinesia (involuntary movements) and fluctuations in motor response. Further, disease progression is associated with the development of dementia, autonomic dysfunction, and postural instability, which do not respond to levodopa therapy. Accordingly, research efforts have been directed toward understanding the etiology and pathogenesis of PD in the hope of developing a more effective therapy that will slow or halt the natural progression of PD. This paper reviews recent advances.

[1]  V. Hamburger,et al.  A diffusible agent of mouse sarcoma, producing hyperplasia of sympathetic ganglia and hyperneurotization of viscera in the chick embryo , 1953 .

[2]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[3]  W. Nicklas,et al.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.

[4]  B. Halliwell,et al.  Oxygen radicals and the nervous system , 1985, Trends in Neurosciences.

[5]  R. Ramsay,et al.  Biochemical Events in the Development of Parkinsonism Induced by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine , 1987, Journal of neurochemistry.

[6]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[7]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[8]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[9]  E. Pileblad,et al.  Reduction of Brain Glutathione by l‐Buthionine Sulfoximine Potentiates the Dopamine‐Depleting Action of 6‐Hydroxydopamine in Rat Striatum , 1989, Journal of neurochemistry.

[10]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[11]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[12]  J. Langston,et al.  Oxidation reactions in Parkinson's disease. Discussion , 1990 .

[13]  J. Langston,et al.  Effects of 1‐Methyl‐4‐Phenyl‐ 1,2,3,6‐Tetrahydropyridine and 1 ‐Methyl‐4‐Phenylpyridinium Ion on ATP Levels of Mouse Brain Synaptosomes , 1990, Journal of neurochemistry.

[14]  Olanow Cw Oxidation reactions in Parkinson's disease. , 1990 .

[15]  B. Freeman,et al.  Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Jellinger,et al.  Normal Mitochondrial Genome in Brain from Patients with Parkinson's Disease and Complex I Defect , 1990, Journal of neurochemistry.

[17]  M. Delong,et al.  Primate models of movement disorders of basal ganglia origin , 1990, Trends in Neurosciences.

[18]  C. Tanner,et al.  Do environmental toxins cause Parkinson's disease? A critical review , 1990, Neurology.

[19]  L. Golbe The genetics of Parkinson's disease: A reconsideration , 1990, Neurology.

[20]  C. Olanow Oxidation reactions in Parkinson's disease , 1990, Neurology.

[21]  P. Löschmann,et al.  Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.

[22]  S. Snyder,et al.  Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. Yancopoulos,et al.  BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra , 1991, Nature.

[24]  C. W. Olanow,et al.  Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study , 1992, Brain Research.

[25]  K. Jellinger,et al.  Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease , 1992, Neuroscience Letters.

[26]  M. Beal,et al.  Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.

[27]  E. Stefani,et al.  A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[28]  S. Varon,et al.  Ciliary neurotrophic factor prevents neuronal degeneration and promotes low affinity NGF receptor expression in the adult rat CNS , 1992, Neuron.

[29]  R. North,et al.  Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump. , 1992, Science.

[30]  J S Beckman,et al.  Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. , 1992, Archives of biochemistry and biophysics.

[31]  S. Varon,et al.  Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[32]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[34]  S. Dimauro,et al.  Mitochondria1 involvement in Parkinson's disease , 1993, Neurology.

[35]  C. Mytilineou,et al.  Toxic and Protective Effects of l‐DOPA on Mesencephalic Cell Cultures , 1993, Journal of neurochemistry.

[36]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[37]  C. Olanow A radical hypothesis for neurodegeneration , 1993, Trends in Neurosciences.

[38]  C. Olanow,et al.  Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers , 1993, Journal of neuroscience research.

[39]  S. Daniel,et al.  Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.

[40]  C. Marsden,et al.  Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study , 1994, Movement disorders : official journal of the Movement Disorder Society.

[41]  Mitsutoshi Yamamoto,et al.  Differential effects of chronic l-DOPA treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine , 1994, Neuroscience Letters.

[42]  C. Olanow,et al.  Progressive Changes in Striatal Dopaminergic Markers, Nigral Volume, and Rotational Behavior Following Iron Infusion into the Rat Substantia Nigra , 1994, Experimental Neurology.

[43]  N. Hattori,et al.  An immunohistochemical study on α‐ketoglutarate dehydrogenase complex in Parkinson's disease , 1994 .

[44]  C. Marsden,et al.  Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.

[45]  K. Fuxe,et al.  Temporal and spatial increase of astroglial basic fibroblast growth factor synthesis after 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine neurons , 1994, Neuroscience.

[46]  R. Kurlan,et al.  Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease , 1994, Annals of neurology.

[47]  F. Watt,et al.  Increased Iron in the Substantia Nigra Compacta of the MPTP‐Lesioned Hemiparkinsonian African Green Monkey: Evidence from Proton Microprobe Elemental Microanalysis , 1994, Journal of neurochemistry.

[48]  J. Rothstein,et al.  Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[49]  C. Olanow,et al.  Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study , 1994, Brain Research.

[50]  M. Shelanski,et al.  Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Newmeyer,et al.  Cell-free apoptosis in Xenopus egg extracts: Inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria , 1994, Cell.

[52]  C. Marsden,et al.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.

[53]  D. Holland,et al.  (−)‐Deprenyl Reduces PC12 Cell Apoptosis by Inducing New Protein Synthesis , 1994, Journal of neurochemistry.

[54]  J. Gusella,et al.  Genetic linkage studies in autosomal dominant parkinsonism: Evaluation of seven candidate genes , 1994, Annals of neurology.

[55]  J. Hubble,et al.  The effect of deprenyl and levodopa on the progression of Parkinson's disease , 1995, Annals of neurology.

[56]  J. Connor,et al.  A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains , 1995, Journal of neurochemistry.

[57]  L. Rubin,et al.  A c-jun dominant negative mutant protects sympathetic neurons against programmed cell death , 1995, Neuron.

[58]  J. Schulz,et al.  Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity , 1995, Experimental Neurology.

[59]  Y. Agid [Aging, disease and nerve cell death]. , 1995, Bulletin de l'Academie nationale de medecine.

[60]  C. Waters,et al.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. , 1995, The Journal of clinical investigation.

[61]  Y Agid,et al.  Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Point mutations of mitochondrial genome in Parkinson's disease , 1995 .

[63]  David F. Clayton,et al.  Characterization of a novel protein regulated during the critical period for song learning in the zebra finch , 1995, Neuron.

[64]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[65]  Guido Kroemer,et al.  The biochemistry of programmed cell death , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[66]  J. Schulz,et al.  Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.

[67]  T. Ozawa,et al.  Point mutations of mitochondrial genome in Parkinson's disease. , 1995, Brain research. Molecular brain research.

[68]  N. Ip,et al.  Time course of ciliary neurotrophic factor mRNA expression is coincident with the presence of protoplasmic astrocytes in traumatized rat striatum , 1995, Journal of neuroscience research.

[69]  B J Hoffer,et al.  Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys , 1995, The Journal of comparative neurology.

[70]  Y. Mizuno,et al.  bcl-2 Protein is increased in the brain from parkinsonian patients , 1996, Neuroscience Letters.

[71]  M. Beal,et al.  Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons , 1996, Nature Medicine.

[72]  W. Tatton,et al.  Reduction of neuronal apoptosis by small molecules: Promise for new approaches to neurological therapy , 1996 .

[73]  M. Polymeropoulos,et al.  Mapping of a Gene for Parkinson's Disease to Chromosome 4q21-q23 , 1996, Science.

[74]  J. Glowinski,et al.  Astrocytes protect neurons from hydrogen peroxide toxicity , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[75]  A. Benabid,et al.  Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies , 1996, The European journal of neuroscience.

[76]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[77]  D. Chuang,et al.  An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. , 1996, The Journal of pharmacology and experimental therapeutics.

[78]  J. Bolaños,et al.  Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione. , 1996, Free radical biology & medicine.

[79]  G. Kroemer,et al.  Bcl-2 inhibits the mitochondrial release of an apoptogenic protease , 1996, The Journal of experimental medicine.

[80]  Y. Mizuno,et al.  Histochemical detection of apoptosis in Parkinson's disease , 1996, Journal of the Neurological Sciences.

[81]  G. Davey,et al.  Threshold Effects and Control of Oxidative Phosphorylation in Nonsynaptic Rat Brain Mitochondria , 1996, Journal of neurochemistry.

[82]  C. Olanow,et al.  Oxidative stress and the pathogenesis of Parkinson's disease , 1996, Neurology.

[83]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[84]  C. Olanow,et al.  Iron and neurodegeneration , 1996 .

[85]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[86]  W. Tatton Modulation of gene expression rather than monoamine oxidase inhibition , 1996, Neurology.

[87]  M. Memo,et al.  Neuroprotection by Aspirin and Sodium Salicylate Through Blockade of NF-κB Activation , 1996, Science.

[88]  P. Lansbury,et al.  NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.

[89]  Annette M. Schmid,et al.  Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones , 1996, Neuroreport.

[90]  K. Davis,et al.  A pilot study of prednisone in Alzheimer's disease. , 1996, Dementia.

[91]  S. Sakoda,et al.  Pentoxifylline delays the onset of experimental allergic encephalomyelitis in mice by modulating cytokine production in peripheral blood mononuclear cells. , 1996, Immunopharmacology.

[92]  R. Swerdlow,et al.  Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.

[93]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[94]  C. Olanow,et al.  l‐(−)‐Desmethylselegiline, a Metabolite of Selegiline [l‐(−)‐Deprenyl], Protects Mesencephalic Dopamine Neurons from Excitotoxicity In Vitro , 1997, Journal of neurochemistry.

[95]  S. Kish,et al.  In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.

[96]  J. H. Li,et al.  Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[97]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[98]  K. Castagnoli,et al.  The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1997, Chemical research in toxicology.

[99]  S. Jiao,et al.  Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery , 1997, Neuroscience.

[100]  C. Marsden,et al.  Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease , 1997, The Lancet.

[101]  C D Marsden,et al.  Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.

[102]  Y Agid,et al.  Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[103]  Y. Agid,et al.  Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. , 1997, Histology and histopathology.

[104]  W. Tatton,et al.  Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. , 1997, Journal of neural transmission. Supplementum.

[105]  C. Olanow,et al.  l‐Deprenyl Protects Mesencephalic Dopamine Neurons from Glutamate Receptor‐Mediated Toxicity In Vitro , 1997, Journal of neurochemistry.

[106]  A. Lees,et al.  A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease , 1997, Journal of neurochemistry.

[107]  S. Snyder,et al.  Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[108]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[109]  M. Polymeropoulos Autosomal dominant parkinson's disease and α‐synuclein , 1998 .

[110]  L. Scorrano,et al.  The mitochondrial permeability transition , 2022, BioFactors.

[111]  J. Obeso,et al.  Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotection , 1998, Annals of neurology.

[112]  Genetic risk factors in parkinson's disease , 1998, Annals of neurology.

[113]  W. Tatton,et al.  Mitochondrial Membrane Potential and Nuclear Changes in Apoptosis Caused by Serum and Nerve Growth Factor Withdrawal: Time Course and Modification by (؊)-deprenyl , 2022 .

[114]  D. Perl,et al.  A fluorescent double‐labeling method to detect and confirm apoptotic nuclei in parkinson's disease , 1998, Annals of neurology.

[115]  P. Jenner,et al.  Understanding cell death in parkinson's disease , 1998, Annals of neurology.

[116]  P. Damier,et al.  Glial cells and inflammation in parkinson's disease: A role in neurodegeneration? , 1998, Annals of neurology.

[117]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[118]  C. Olanow,et al.  Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. , 1998, The Journal of pharmacology and experimental therapeutics.

[119]  D. Perl,et al.  Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.

[120]  Zhiming Zhang,et al.  Neuroprotective and neurorestorative properties of GDNF , 1998, Annals of neurology.

[121]  T. Jessell,et al.  The specification of dorsal cell fates in the vertebrate central nervous system. , 1999, Annual review of neuroscience.

[122]  B. Wandell Computational neuroimaging of human visual cortex. , 1999, Annual review of neuroscience.

[123]  P. Mombaerts,et al.  Molecular biology of odorant receptors in vertebrates. , 1999, Annual review of neuroscience.

[124]  L. Rubin,et al.  The cell biology of the blood-brain barrier. , 1999, Annual review of neuroscience.

[125]  B. Mueller,et al.  Growth cone guidance: first steps towards a deeper understanding. , 1999, Annual review of neuroscience.

[126]  J. Schall,et al.  Neural selection and control of visually guided eye movements. , 1999, Annual review of neuroscience.

[127]  G. Baltuch,et al.  Microglia as mediators of inflammatory and degenerative diseases. , 1999, Annual review of neuroscience.

[128]  S. Landis,et al.  Cellular and molecular determinants of sympathetic neuron development. , 1999, Annual review of neuroscience.

[129]  W. Betz,et al.  Monitoring secretory membrane with FM1-43 fluorescence. , 1999, Annual review of neuroscience.